Navigation Links
Empi's Hybresis Solves 'Pain Points' for Physical Therapists
Date:1/21/2008

PTs Report Wireless Hybrid Iontophoresis System Delivers Precise Dose Control, Reduces Patient Discomfort and Shortens In-Clinic Treatment Times

ST. PAUL, Minn., Jan. 21 /PRNewswire/ -- For years, physical therapists have relied on iontophoresis as a safe, reliable and effective drug delivery method. At the same time, most PTs have suffered the drawbacks of traditional dose controllers, lead wires and patch-only iontophoresis systems. This traditional system also includes extensive wear times, patient patch sensitivity and imprecise dosage delivery, which can all lead to unpredictable results. The industry's first wireless hybrid iontophoresis system, Hybresis, is a convenient, needle-free drug delivery system that allows clinicians to treat more patients while improving overall care by reducing patient discomfort and inconvenience.

According to the National Institute of Health (NIH), more than 50 million Americans annually suffer from chronic pain. Traditional pain management treatments include needle injections of anti-inflammatory drugs, narcotics, time-consuming in-clinic treatments or surgery -- all of which often result in unnecessary pain, side effects, anxiety or inconvenience for patients. Hybresis significantly reduces the total in-clinic time, enabling PTs to help move more patients through the clinic faster. Ultimately, PTs can spend more time on providing care.

PTs, including Rick Mewes, OCS, who works in a sports medicine clinic in Minneapolis, have reported that the Hybresis system offers the power of the traditional dose controllers and lead wires, with the flexibility of a patch. "With Hybresis, my patients can be treated effectively in less than half the time it takes for traditional iontophoresis," said Mewes. "My patients have also responded favorably -- opting for the convenience that Hybresis offers over other methods. The greatest benefit I've seen from using Hybresis is that I can now spend more time providing therapy, rather than wasting the time that's required for other iontophoresis treatments to be administered."

The Hybresis system consists of a charging station with four controller bays, a wireless, rechargeable controller and an iontophoresis patch. The patches have an internal battery, which powers the delivery of the medicine during and upon removal of the external Hybresis device. The Hybresis Dose Controller connects to the patch and powers a three-minute initial treatment, allowing for increased absorption that leads to more controlled therapy. After three minutes, the Dose Controller is removed and the Patch is powered to deliver the remainder of the therapy to the patient -- providing patients with the mobility to leave the clinic. After approximately one to two hours, the treatment is complete and patients should remove and discard the patch.

Hybresis patient benefits include:

-- Significantly shorter in-clinic and overall wear times

-- A more discreet and comfortable system which reduces the likelihood of

skin irritation

-- A gentle, hypoallergenic patch adhesive and ergonomic design that

conforms to the treatment area

-- Virtually painless treatment without anti-inflammatory injections,

thereby reducing the risk of infection and minimizing potential for

tissue trauma from the needle

"My pain used to prevent me from doing everyday activities like lifting weights, exercising and using some hand tools on do-it-yourself projects," said patient Bob Gubrud, who recently suffered a shoulder injury due to a bike accident. "Since my PT offered Hybresis, the road to recovery has been much faster. I was in and out of the clinic quickly and able to get back to doing my everyday activities feeling pain-free."

"With a continued rise in the aging population and the number of people suffering from chronic pain, America today is facing a pain epidemic. Now more than ever, healthcare professionals need the right tools to treat their patients, who often have a number of concerns about pain management," said Don Dumoulin, President of Empi. "With Hybresis, Empi has taken another step in providing patients with more options for therapeutic relief. Essentially, we've taken the 'pain' out of drug delivery for both patients and the healthcare professionals."

Empi's Hybresis system has regulatory approval through the 510(k) market clearance process of the U.S. Food and Drug Administration (FDA). Prescription by a licensed physician is required.

For more information about Hybresis, please visit http://www.hybresis.com.

About Empi

Empi, a DJO company, is a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. Headquartered in St. Paul, Minnesota, Empi is committed to delivering positive patient outcomes and providing innovative products specifically designed to meet the needs of the patient, medical professional and payor. More information about Empi and its wide range of pain management products and services can be found on the Company's Web site, http://www.empi.com. More information about DJO can be found on the Company's Web Site at http://www.DJOglobal.com.

Media Contact:

Susan Lombardo

Lois Paul & Partners

781.782.5767

susan_lombardo@lpp.com


'/>"/>
SOURCE Empi
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. Whiplash may produce delayed jaw pain
3. Hypnosis Eases Pain of Breast Cancer Surgery
4. Whiplash May Result in Delayed Jaw Pain
5. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
6. Knee Pain May Signal Lung Cancer
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. New study examines brain-gut relationship in those suffering with stomach pain or discomfort
10. Pain patients at risk for sleep apnea
11. Painless Hemorrhoid Treatment Adds Management Punch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... Georgia State University College of Law ... , Answering to the increasing demand for curricular specializations, the Certificate in Intellectual ... and land use law. ,  , “The demand for lawyers with specific knowledge ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the ... Senior Living (SHSL) may not share those same worries thanks to a new ... year, while holding the line on increasing their contributions, including premiums, deductibles and the ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 - ... Pump and Others)" published by P&S Market Research, the ... million in 2015, and it is expected to grow ... type, the insulin pump segment is expected to witness ...
(Date:5/25/2016)... SOUTHLAKE, Texas , May 25, 2016 /PRNewswire/ ... today the issuance to it by the US ...  9,218,608. The company,s technology includes proprietary processes for ... claims for health and wellness programs, HIPAA compliance ... "Our ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology: